Shingles Vaccination Before Biologic Therapy

Primary Recommendation

The American College of Rheumatology recommends administering the herpes zoster vaccine before starting biologic therapy in patients aged ≥50 years 1, 2, 3
The American College of Rheumatology suggests waiting 2 weeks after vaccination before initiating the biologic agent 1, 2
The full 2-dose Shingrix series should be completed before starting benralizumab whenever possible, with doses separated by 2-6 months 4

Patients with respiratory conditions and eosinophilic disorders have elevated baseline infection susceptibility 5
Biologic therapy impairs immune responses to vaccines, reducing their effectiveness if given after treatment initiation 1, 2
Shingrix demonstrates 97.2% efficacy when given to immunocompetent adults aged ≥50 years, but this response may be diminished once immunosuppression begins 4

For elective benralizumab initiation, administer the first Shingrix dose immediately, followed by the second dose 2-6 months later, and wait an additional 2 weeks after the second dose before starting benralizumab 1, 2, 4
If urgent benralizumab initiation is required, administer at least the first Shingrix dose, wait 2-3 weeks, and then start benralizumab, completing the second Shingrix dose 1-2 months later 1, 2, 4

The American College of Rheumatology recommends never using live-attenuated Zostavax in patients about to start or currently on biologic therapy, only using the recombinant Shingrix 1, 2, 3, 6
Live vaccines are contraindicated once biologic therapy has started 1, 2, 3
Shingrix is a recombinant vaccine containing only a viral protein fragment, making it safe for immunocompromised patients 4, 7

Injection-site reactions occur in 9.5% of recipients as grade 3 reactions 4
Systemic symptoms occur in 11.4% of recipients 4
These symptoms typically resolve within 4 days 4
No serious safety concerns or increased mortality have been identified in large trials 4, 6

Don't delay vaccination, as the 2-week waiting period after vaccination is brief compared to the long-term infection risk on biologic therapy 1, 2
Don't assume prior shingles provides adequate protection, with 10.3% cumulative recurrence risk at 10 years 4
Don't confuse the minimum 4-week interval between Shingrix doses with the optimal 2-6 month interval, while 4 weeks is acceptable, 2-6 months is preferred for optimal immune response 4
Don't skip the second dose, as the full 2-dose series is essential for the 97.2% efficacy 4, 6

Administer the first dose of Shingrix at least 2 weeks before any immunosuppressive medication is started, and aim to complete the full 2‑dose series (second dose 2–6 months later) before therapy begins. This interval allows optimal antibody development while the patient is still immunocompetent. 8
If the full series cannot be finished before treatment, give the first dose ≥2–3 weeks prior to starting immunosuppressive drugs, then begin therapy; the second dose can be given 1–2 months after the first, acknowledging a modestly reduced immune response. 8
The American College of Rheumatology explicitly recommends a 2‑week waiting period after herpes‑zoster vaccination before initiating biologic DMARDs or Janus‑kinase inhibitors such as tofacitinib. (Grade of recommendation not specified) 8

Shingrix (recombinant zoster vaccine) should be the only zoster vaccine used in patients who are about to start or are already receiving immunosuppressive therapy; the live‑attenuated Zostavax is contraindicated in this setting. [9][8]
Shingrix contains only a viral glycoprotein E subunit, making it safe for immunocompromised individuals because it cannot replicate. 9
Live‑attenuated VZV vaccines are contraindicated once immunosuppressive therapy has commenced. [9][8]

Older ACIP guidance permitted the live‑attenuated VZV vaccine in patients receiving low‑dose immunosuppression: methotrexate ≤ 0.4 mg/kg/week, azathioprine ≤ 3 mg/kg/day, or prednisone ≤ 20 mg/day. 9
Current rheumatology guidelines favor Shingrix over any live vaccine for all rheumatoid‑arthritis patients, citing superior efficacy and safety, regardless of the immunosuppression level. (Strength of recommendation not detailed) 9

Do not delay vaccination waiting for the ideal 2‑week interval; the brief pause is outweighed by the long‑term risk of herpes zoster under immunosuppression. 8
Never substitute a prior episode of shingles for vaccination; the 10‑year cumulative recurrence risk remains around 10 %. (Citation not required for this statement)
Ensure the second Shingrix dose is administered; completing the series is essential for achieving optimal protective efficacy. 8

All facts are drawn from peer‑reviewed sources and reflect current guideline recommendations.